Acute Myeloid Leukemia (AML)

Dr. Navada is an assistant professor in the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York City. She attended medical school at the University of Illinois at Chicago. Subsequently, she did an Internal Medicine Residency at the University of Michigan in Ann Arbor prior to completing a hematology/oncology fellowship at Mount Sinai. She is currently completing a Masters of Science in Clinical Research in the graduate school at Mount Sinai. Her primary clinical and research interests are myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the

Joachim Deeg, MD is a member of the Fred Hutchinson Cancer Research Center in Seattle, Washington and professor of medicine at the University of Washington. He is also a member of the AA&MDSIF Medical Advisory Board.

Dr. Graubert’s research focuses on the molecular pathogenesis of myeloid leukemias. While at Washington University in St. Louis, he and his colleagues used genome sequencing technology extensively to gain insights into the genetic basis of human cancer and to use this information to improve risk stratification tools and identify targets for novel therapy. Their group published the first complete genome sequence of a human cancer (acute myeloid leukemia) in 2008 and in subsequent publications described novel recurrent mutations in IDH2 and DNMT3A that have prognostic significance in acute

Dr. Amy DeZern is a hematologist and medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and is an Assistant Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. She received her medical degree in 2005 from the Johns Hopkins University School of Medicine and her Master in Clinical Investigation (M.H.S.) from the Johns Hopkins Bloomberg School of Public Health. She completed residency training in internal medicine as well as fellowships in medical oncology and hematology at Johns Hopkins. Dr. DeZern sees patients at the Sidney Kimmel

B. Douglas Smith is Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, and is on the active staff of Johns Hopkins Hospital. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed an internship, residency, and chief residency at Strong Memorial Hospital in Rochester, New York. At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies. Dr. Smith’s research focuses on taking new and promising laboratory insights and

Dr. Rossetti earned his Doctor of Osteopathic Medicine degree from the Lake Erie College of Osteopathic Medicine and completed an internship and internal medicine residency at St. Francis Medical Center of Pittsburgh. He did fellowship training in hematology and medical oncology at The Western Pennsylvania Hospital and is board certified in medical oncology and hematology. He is an assistant professor at the Temple University School of Medicine and an adjunct clinical instructor for the Lake Erie College of Osteopathic Medicine. Dr. Rossetti is a recognized expert in hematological malignancy

Dr. Michael Keng holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital. His clinical areas of interest are: myelodysplastic syndromes, myeloproliferative disorders, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoid leukemia, and aplastic anemia. He attended medical school at Michigan State University in East Lansing, Michigan and completed internal medicine residency at University of Southern